On the heels of last week’s letter from 51 U.S. senators to the Food and Drug Administration and Department of Health and Human Services, HELP Committee Chairman Bill Cassidy sent an oversight letter today demanding answers from Secretary Robert F. Kennedy and Commissioner Marty Makary.
Get the latest pro-life news and information on X (Twitter). Follow @LifeNewsHQ
Lawmakers are turning up the pressure after the FDA approved a new generic abortion drug in the wake of the Biden administration’s rollback of commonsense safeguards that required in-person doctor visits. The Biden FDA’s mail-order abortion policy, which is inexplicably still in effect, recklessly endangers women and unborn children while undermining state pro-life laws. All of this comes despite promises from Secretary Kennedy and Commissioner Makary that the FDA would conduct a serious review of abortion drug safety.
The letter states:
“In light of the FDA’s approval of another means of chemical abortion under the same flawed REMS framework, it is imperative that you provide an update on your review of mifepristone and your plans to reinstate necessary safeguards. To be clear: this approval fails to mitigate the risks to women that have been identified and fails to protect women from the coercive use of the drug.”
Susan B. Anthony Pro-Life America President Marjorie Dannenfelser issued the following statement:
“It is time for Secretary Kennedy and Commissioner Makary to act. Abortion drugs are taking the lives of unborn children, risking the lives of women across America, and undermining the sovereignty of states’ pro-life laws. Women, children and our citizens deserve better. The lawlessness surrounding the distribution of these drugs – kicking the physician out of the doctor-patient relationship – has put drugs in the hands of abusers of underage girls and women. The horror stories and facts roll in daily, yet the response from the FDA was to approve a cheaper version of a drug that ends unborn lives and sends women to the ER. We are deeply grateful to Chairman Cassidy and his Senate colleagues for leading this critical oversight letter to the FDA.”
